Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Prostate cancer

Better VISTAs ahead? Potential and pitfalls of immunotherapy

Nature Reviews Urology volume 14, pages 455–456 (2017)Cite this article

Subjects

Despite a rapid increase in the use of anticancer immunotherapy, our understanding of the mechanisms of action and the patients' responses remains limited. The discovery of immune inhibitory markers in the tumour microenvironment following immunotherapy should improve our understanding and might enable us to better apply combination therapies.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Gao, J. et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat. Med. 23, 551–555 (2017).

    Article  CAS  Google Scholar 

  2. Fong, L. et al. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J. Natl Cancer Inst. 106, dju268 (2014).

    Article  Google Scholar 

  3. Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411–422 (2010).

    Article  CAS  Google Scholar 

  4. Beer, T. M. et al. Randomized, double-blind, Phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J. Clin. Oncol. 35, 40–47 (2017).

    Article  CAS  Google Scholar 

  5. Graff, J. N. et al. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget 7, 52810–52817 (2016).

    PubMed  PubMed Central  Google Scholar 

  6. Kwon, E. D. et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 15, 700–712 (2014).

    Article  CAS  Google Scholar 

  7. Benci, J. L. et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell 167, 1540–1554.e12 (2016).

    Article  CAS  Google Scholar 

  8. Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).

    Article  Google Scholar 

  9. Nowak, E. C. et al. Immunoregulatory functions of VISTA. Immunol. Rev. 276, 66–79 (2017).

    Article  CAS  Google Scholar 

  10. Dhodapkar, K. M. et al. Distinct dominant T-cell receptors with a tissue resident memory phenotype in individual melanoma metastases [abstract]. J. Clin. Oncol. 35 (suppl 7S), 3 (2017).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ravi A. Madan and James L. Gulley are at the Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive 13N240, Bethesda, Maryland 20892, USA.,

    Ravi A. Madan & James L. Gulley

Authors
  1. Ravi A. Madan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James L. Gulley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James L. Gulley.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Madan, R., Gulley, J. Better VISTAs ahead? Potential and pitfalls of immunotherapy. Nat Rev Urol 14, 455–456 (2017). https://doi.org/10.1038/nrurol.2017.75

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2017.75

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing